The purpose — of the study is to evaluate the effectiveness of Multi-Gyn Actigel in the treatment of pregnant women with bacterial vaginosis. Material and methods. Seventy-five (75) pregnant women with bacterial vaginosis who wished to limit their exposure to antibiotics were treated with Multi-Gyn Actigel as a monotherapy; another 75 pregnant women were treated with a combination of drugs including an anti-anaerobic component, by use of vaginal suppositories for 7—10 days. Multi-Gyn Actigel was administered according to the instructions, twice a day for 5—7 days. Afterwards, all patients monitored their vaginal pH levels themselves using test strips. If the vaginal pH level increased to more than 4.7, the drug treatment was repeated. The efficacy of the use of Multi-Gyn Actigel for the treatment of pregnant women with bacterial vaginosis was assessed on the basis of a comparison of the results of pre-treatment examinations (when patients were first diagnosed with bacterial vaginosis) within a gestation period of 32—37 weeks, and then after treatment (at the time of prenatal examinations). Results. The positive effect of Multi-Gyn Actigel is demonstrated by the elimination or reduction of symptoms of bacterial vaginosis, and the restoration of optimal vaginal pH levels. The use of Multi-Gyn Actigel in pregnant women is safe. It has no side effects or other negative effects. Poor drug tolerance was not reported by any patient. The use of Multi-Gyn Actigel in pregnant women with bacterial vaginosis reduces the absolute risk of bacterial vaginosis recurrence by 52.0% (95% CI 38.5—65.5), and the relative risk by 62.9% (95% CI 47.1—74.0). This represents a clinically significant effect, and indicates that the number of patients to be treated is 1.9 (95% CI 1.5—2.6). Conclusion. The use of Multi-Gyn Actigel for the treatment of bacterial vaginosis in pregnant women can be considered an appropriate treatment.